WuXi Biologics (Cayman) (FRA:1FW2) Ending Cash Position : €1,242 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Ending Cash Position?

WuXi Biologics (Cayman)'s Ending Cash Position for the quarter that ended in Dec. 2023 was €1,242 Mil.

WuXi Biologics (Cayman)'s quarterly Ending Cash Position increased from Dec. 2022 (€866 Mil) to Jun. 2023 (€948 Mil) and increased from Jun. 2023 (€948 Mil) to Dec. 2023 (€1,242 Mil).

WuXi Biologics (Cayman)'s annual Ending Cash Position declined from Dec. 2021 (€1,251 Mil) to Dec. 2022 (€866 Mil) but then increased from Dec. 2022 (€866 Mil) to Dec. 2023 (€1,242 Mil).

WuXi Biologics (Cayman) Ending Cash Position Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Ending Cash Position Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

796.29

891.95

1,250.99

865.94

1,241.88

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial													1,250.99	1,149.48	865.94	947.97	1,241.88

WuXi Biologics (Cayman) Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

WuXi Biologics (Cayman)'s Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	821.324	+	420.552
	=	1,242

WuXi Biologics (Cayman)'s Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	944.604	+	297.272
	=	1,242

WuXi Biologics (Cayman) Ending Cash Position Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines